CJC-1295 doesn't add growth hormone — it tells your own pituitary to make more. It copies GHRH, the natural "release growth hormone" signal, but is re-engineered to survive far longer in the body. The DAC version grabs onto albumin (the most abundant blood protein) so a single shot keeps gently nudging the pituitary for about a week. Crucially, it raises the height and floor of your natural GH pulses while leaving the rhythm intact — unlike injecting GH directly, which flattens that rhythm. The extra GH then drives the liver to make IGF-1, the hormone behind most of GH's effects on muscle, fat, and recovery.
Six mechanistically linked arms. First — high-affinity agonism at the GHRH receptor (GHRHR), a class B GPCR on anterior-pituitary somatotrophs, amplifying GH pulse amplitude and trough levels. Second — DAC albumin binding: the maleimidopropionyl-lysine linker covalently bonds albumin Cys34, transforming the peptide into a ~69 kDa depot and extending t½ to 5.8–8.1 days. Third — the canonical Gαs → adenylyl cyclase → cAMP → PKA → CREB cascade with Ca²⁺-driven exocytosis. Fourth — downstream hepatic IGF-1 synthesis (1.5–3× for 9–28 days). Fifth — DPP-IV resistance from the D-Ala² substitution. Sixth — preservation of pulsatility, because endogenous somatostatin continues to brake GH release even under sustained GHRH stimulation.
CJC-1295 is a GHRHR agonist whose distinguishing pharmacology is kinetic, not target-novel. Robinson/ConjuChem (Endocrinology 2005, PMID 15817669) established that hGRF(1-29)–albumin bioconjugates activate the pituitary GRF receptor in rats and identified CJC-1295 as the long-lasting lead. The maleimide–thiol reaction with albumin Cys34 is essentially irreversible under physiological conditions, creating a circulating depot that re-engages GHRHR across multiple endogenous pulse windows. Downstream, GH binds hepatic GHR → JAK2/STAT5b → IGF-1 transcription; circulating IGF-1 activates IGF1R tyrosine kinase → PI3K/Akt/mTOR and MAPK/ERK — the same mitogenic cascade epidemiologically linked to several cancers, which is the mechanistic basis for the oncology caution. No human receptor-occupancy/EC50 dataset for the engineered analog has been published.
B
🎯
GHRH receptor agonism (primary)
The core mechanism. CJC-1295 is a high-affinity agonist at the GHRH receptor on anterior-pituitary somatotrophs, preserving pulsatile GH secretion while amplifying both pulse amplitude and trough levels. In healthy adults this produced dose-dependent 2–10× GH elevation lasting ≥6 days.
Clinical significance: Amplifying endogenous pulsatile GH — rather than imposing tonic exogenous GH — is the central therapeutic rationale. Supraphysiological flat GH (as with rhGH) is associated with greater insulin resistance and acromegalic effects; pulse amplification is theoretically gentler, though this advantage has never been demonstrated on a clinical endpoint.
Molecular detail: GHRHR is a class B (secretin-family) seven-transmembrane GPCR. CJC-1295 engages both the large extracellular N-terminal domain and the transmembrane helical bundle, recruiting Gαs → adenylyl cyclase. No published Ki/EC50 exists for the engineered analog in human tissue, so a target-engagement PK/PD model cannot currently be constructed.
B
🧲
DAC albumin-binding · PK extension
The defining feature of the DAC variant. A maleimidopropionyl (MPA) linker at the C-terminus forms a covalent thioether bond with Cys34 of serum albumin within minutes of injection, turning the ~3.4 kDa peptide into an effective ~69 kDa albumin–peptide conjugate. This blocks DPP-IV cleavage and renal filtration, extending half-life to 5.8–8.1 days.
Clinical significance: The 8-day half-life enables once-weekly dosing but also means that any adverse effect — water retention, IGF-1 over-elevation — persists for over a week after the last dose and cannot be rapidly reversed. This is the single most important practical difference from short-acting GHRH analogs.
Molecular detail: The maleimide–thiol reaction is essentially irreversible at physiological pH. Albumin functions as a circulating depot; as albumin–CJC-1295 slowly turns over, the peptide re-engages GHRHR across multiple endogenous GH-pulse windows. The bioconjugate strategy and receptor activation were validated in rats before human translation.
P
⚡
Adenylyl cyclase · cAMP · PKA cascade
Once bound, GHRHR activation via Gαs stimulates adenylyl cyclase, raising intracellular cAMP, activating PKA, opening voltage-gated calcium channels, and triggering exocytosis of GH-containing secretory granules. This is the established GHRH signal-transduction route applied to the engineered analog.
Clinical significance: Because the secretory step depends on existing somatotroph GH stores and intact downstream machinery, CJC-1295 cannot release GH a pituitary cannot make — a relevant limit in severe pituitary disease, and the reason it is a secretagogue, not a replacement.
Molecular detail: PKA phosphorylates CREB at Ser133, activating CRE-mediated transcription of the GH1 gene; PKA simultaneously potentiates L-type Ca²⁺ channels, and the resulting [Ca²⁺]i rise is the direct trigger for granule exocytosis. This pathway is drawn from general GHRH molecular pharmacology, not CJC-1295-specific cell studies — hence grade P.
B
🫀
IGF-1 axis activation (downstream)
The GH released downstream travels to the liver and drives IGF-1 production — the mediator of most of GH's body-composition and anabolic effects. Clinical studies show 1.5–3× IGF-1 elevation lasting 9–11 days after a single dose, and up to 28 days after multiple doses.
Clinical significance: Serum IGF-1 is the practical pharmacodynamic marker for CJC-1295 — the one biomarker actually validated in the Phase I program — and the safety governor: IGF-1 driven far above the age-adjusted reference range is the trigger for de-escalation or stopping.
Molecular detail: GH binds hepatocyte GHR → JAK2/STAT5b → IGF-1 gene transcription. Circulating IGF-1 binds IGF1R (receptor tyrosine kinase) → PI3K/Akt/mTOR and MAPK/ERK, mediating protein synthesis, lipolysis, and mitogenic/anti-apoptotic effects — the latter the basis of the theoretical tumor-promotion concern.
C
🛡️
DPP-IV resistance (enzymatic stability)
Native GHRH(1-29) is inactivated within minutes by dipeptidyl peptidase-IV (DPP-IV), which cleaves after the Ala at position 2. The D-Ala² substitution in CJC-1295 confers intrinsic DPP-IV resistance, extending the No-DAC half-life from ~7 minutes to ~30 minutes — and providing the stable backbone that the DAC further extends.
Clinical significance: This is why the No-DAC form ("Mod GRF 1-29") is usable at all without the DAC. Even so, the ~30-minute half-life means No-DAC must be dosed daily-to-BID and is nearly always paired with a GHRP for a clinically meaningful pulse.
Molecular detail: DPP-IV (CD26) is a serine protease that cleaves N-terminal dipeptides after Pro/Ala at position 2; the D-stereoisomer at Ala² sterically and electronically prevents recognition. The additional Gln⁸, Ala¹⁵, and Leu²⁷ substitutions reduce susceptibility to other proteases (trypsin-like and chymotrypsin-like cleavage).
B
🌊
GH pulsatility preservation
Unlike exogenous rhGH, CJC-1295 preserves the body's natural GH rhythm of peaks and troughs. Even during continuous GHRH stimulation from the DAC form, endogenous somatostatin continues to periodically inhibit pituitary GH release, maintaining pulsatile secretion (Ionescu & Frohman 2006).
Clinical significance: Preserved pulsatility is the headline safety argument for GHRH analogs over direct GH: tonic supra-physiological GH is more strongly tied to insulin resistance and acromegalic change. CJC-1295 amplifies trough GH ~7.5× and mean GH 2–10× while keeping the peak-to-trough rhythm.
Molecular detail: Intact hypothalamic somatostatin (SRIF) neurons cyclically suppress somatotroph responsiveness, gating the amplified GHRH signal into discrete pulses rather than a flat elevation. This is the mechanistic distinction from rhGH and the reason the molecule was pursued as a more physiologic GH therapy.